Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Price Reaction to Earnings Reports

View detailed tables showing price action before and after earnings announcements, ranging from intraday to one week out. Track how the market has reacted to past earnings to identify patterns and predict future behavior. Click here to open.

ANEB

Anebulo Pharmaceuticals Inc

Dec 13 • 04:00PM ET

1.40

Dollar change +0.01
Percentage change 0.72	%

Healthcare • Biotechnology • USA • NASD

Peers: AXSM BTAI BHVN INVA CYTK EOLS GERN EBS ELDN

| Held by: VTI VXF IWC

Scroll to Statements

Index	-	P/E	-	EPS (ttm)	-0.31	Insider Own	64.22%	Shs Outstand	25.93M	Perf Week	-3.11%
Market Cap	36.57M	Forward P/E	-	EPS next Y	-	Insider Trans	0.00%	Shs Float	9.28M	Perf Month	-9.68%
Income	-7.92M	PEG	-	EPS next Q	-0.08	Inst Own	28.32%	Short Float	0.07%	Perf Quarter	-33.01%
Sales	0.00M	P/S	-	EPS this Y	-3.13%	Inst Trans	1.86%	Short Ratio	0.69	Perf Half Y	-33.96%
Book/sh	0.07	P/B	19.12	EPS next Y	-	ROA	-137.58%	Short Interest	0.01M	Perf Year	-34.88%
Cash/sh	0.05	P/C	26.12	EPS next 5Y	-	ROE	-154.87%	52W Range	1.25 - 3.30	Perf YTD	-42.15%
Dividend Est.	-	P/FCF	-	EPS past 5Y	-155.95%	ROI	-417.21%	52W High	-57.58%	Beta	-1.09
Dividend TTM	-	Quick Ratio	3.45	Sales past 5Y	0.00%	Gross Margin	-	52W Low	12.00%	ATR (14)	0.14
Dividend Ex-Date	-	Current Ratio	3.45	EPS Y/Y TTM	32.37%	Oper. Margin	-	RSI (14)	40.77	Volatility	9.27% 10.38%
Employees	3	Debt/Eq	0.00	Sales Y/Y TTM	-	Profit Margin	-	Recom	1.00	Target Price	8.00
Option/Short	No / Yes	LT Debt/Eq	0.00	EPS Q/Q	12.29%	Payout	-	Rel Volume	1.82	Prev Close	1.39
Sales Surprise	-	EPS Surprise	-60.00%	Sales Q/Q	-	Earnings	Nov 13 AMC	Avg Volume	9.28K	Price	1.40
SMA20	-5.06%	SMA50	-16.75%	SMA200	-36.96%	Trades		Volume	16,856	Change	0.72%

Nov-13-24 04:05PM	Anebulo Pharmaceuticals Reports First Quarter Fiscal Year 2025 Financial Results and Recent Updates (Business Wire) -6.06%
Sep-25-24 04:05PM	Anebulo Pharmaceuticals Reports Fourth Quarter and Fiscal Year 2024 Financial Results and Recent Updates (Business Wire) -11.48% +5.95%
Jul-22-24 07:00AM	Anebulo Pharmaceuticals Awarded NIDA Grant for its Investigational IV Treatment for Acute Cannabis-Induced Toxic Effects (Business Wire) +9.09%
Jul-01-24 08:00AM	Lifecore Biomedical Announces Cooperation Agreement with 22NW (GlobeNewswire)
May-15-24 09:55PM	ANEB Stock Earnings: Anebulo Pharmaceuticals Beats EPS for Q3 2024 (InvestorPlace) -6.36%
01:05PM	Loading…
01:05PM	Anebulo Pharmaceuticals Reports Third Quarter Fiscal Year 2024 Financial Results and Recent Updates (Business Wire)
Feb-13-24 04:05PM	Anebulo Pharmaceuticals Reports Second Quarter Fiscal Year 2024 Financial Results and Recent Updates (Business Wire) +5.43%
Nov-14-23 04:05PM	Anebulo Pharmaceuticals Reports First Quarter Fiscal Year 2024 Financial Results and Recent Updates (Business Wire) +5.19%
Oct-19-23 09:40AM	Are Medical Stocks Lagging Anebulo Pharmaceuticals (ANEB) This Year? (Zacks) +13.67%
Oct-06-23 04:06PM	Anebulo Pharmaceuticals Announces New CEO (Business Wire)
04:06PM	Anebulo Pharmaceuticals Announces Appointment of Bimal Shah to its Board of Directors (Business Wire)
Oct-03-23 09:40AM	Are Medical Stocks Lagging Exact Sciences (EXAS) This Year? (Zacks)
Sep-21-23 10:06AM	Enphase Energy upgraded, Brighthouse downgraded: Wall Street's top analyst calls (The Fly)
Sep-20-23 04:29PM	Anebulo Pharmaceuticals Reports Fourth Quarter and Fiscal Year 2023 Financial Results and Recent Updates (Business Wire)
Aug-30-23 08:00AM	Anebulo Pharmaceuticals to Present at Upcoming Investor and Scientific Conferences (Business Wire) +6.92%
09:37AM	Loading…
Aug-22-23 09:37AM	Anebulo (ANEB) Gains on Positive FDA Response for ANEB-001 (Zacks) -5.83%
Aug-21-23 08:00AM	Anebulo Receives Positive Feedback from FDA on Path to Advance Phase 3 Clinical Development of ANEB-001 and Completes Dosing of Phase 2 Extension (Business Wire) +10.36%
Aug-15-23 10:20AM	Sidoti Events, LLCs Virtual August Micro-Cap Conference (ACCESSWIRE)
Jun-12-23 09:40AM	Is Anebulo Pharmaceuticals (ANEB) Outperforming Other Medical Stocks This Year? (Zacks) -5.66%
May-30-23 08:33AM	We Think Anebulo Pharmaceuticals (NASDAQ:ANEB) Needs To Drive Business Growth Carefully (Simply Wall St.)
May-24-23 09:40AM	Has Anebulo Pharmaceuticals (ANEB) Outpaced Other Medical Stocks This Year? (Zacks)
May-19-23 09:35AM	Down -26.43% in 4 Weeks, Here's Why You Should You Buy the Dip in Anebulo Pharmaceuticals, Inc. (ANEB) (Zacks)
May-11-23 08:00AM	Anebulo Pharmaceuticals Reports Third Quarter Fiscal 2023 Financial Results and Recent Updates (PR Newswire)
Mar-28-23 08:00AM	Anebulo Pharmaceuticals Announces Positive Complete Phase 2 Clinical Data Demonstrating Potential of ANEB-001 as a Treatment for Acute Cannabinoid Intoxication (PR Newswire)
Mar-08-23 08:00AM	Anebulo Pharmaceuticals Expands its Integrated and Outsourced Solutions (PR Newswire) -6.33%
Feb-14-23 09:30AM	Sidoti & Company, LLC Announces Registration Now Open for March Small-Cap and May Micro-Cap Conferences (ACCESSWIRE)
Feb-10-23 08:38AM	Anebulo Pharmaceuticals Reports Second Quarter Fiscal Year 2023 Financial Results and Recent Updates (Business Wire)
Jan-09-23 08:00AM	Anebulo Pharmaceuticals Announces Completion of Dosing and Preliminary Data from Part B of its Phase 2 Study of ANEB-001 for Acute Cannabinoid Intoxication (Business Wire)
Dec-21-22 05:42AM	Companies Like Anebulo Pharmaceuticals (NASDAQ:ANEB) Are In A Position To Invest In Growth (Simply Wall St.) +15.52%
Nov-10-22 08:00AM	Anebulo Pharmaceuticals Reports First Quarter Fiscal Year 2023 Financial Results and Recent Updates (Business Wire)
04:00PM	Loading…
Nov-01-22 04:00PM	Anebulo Pharmaceuticals Announces Appointment of Nat Calloway, Ph.D., to Board of Directors (Business Wire) +20.33% -5.52%
Sep-26-22 08:56AM	Lower Doses Of Anebulo's ANEB-001 Reduces Negative Effects Of Higher Doses Of THC (Benzinga)
07:00AM	Anebulo Pharmaceuticals Announces Positive Interim Data for ANEB-001 from Part B of its Phase 2 Clinical Trial for Acute Cannabinoid Intoxication (Business Wire)
07:00AM	Anebulo Pharmaceuticals Announces $6.6 Million Private Placement Financing (Business Wire)
Sep-20-22 08:00AM	Anebulo Pharmaceuticals to Webcast R&D Day on September 26, 2022 (Business Wire) -5.88%
Sep-09-22 08:00AM	Anebulo Pharmaceuticals Reports Fourth Quarter and Fiscal Year 2022 Financial Results and Highlights Recent Business Progress (Business Wire)
Aug-23-22 05:00PM	Anebulo Pharmaceuticals to Host Inaugural R&D Day in New York City on Monday, September 26 (Business Wire) -7.78% +6.37%
Aug-16-22 03:00PM	Sidoti's August Micro-Cap Virtual Conference (ACCESSWIRE)
Jul-14-22 06:23AM	We're Hopeful That Anebulo Pharmaceuticals (NASDAQ:ANEB) Will Use Its Cash Wisely (Simply Wall St.) -22.73%
Jul-05-22 07:57AM	Anebulo's ANEB-001 Reduces Cannabis Intoxication In Healthy Participants (Benzinga)
06:00AM	Anebulo Pharmaceuticals Announces Positive Topline Data for ANEB-001 from a Phase 2 Clinical Trial for Acute Cannabinoid Intoxication (Business Wire)
Jun-23-22 04:00PM	Anebulo Pharmaceuticals to Announce Topline Data for ANEB-001 from an Ongoing Phase 2 Clinical Trial for Acute Cannabinoid Intoxication on Tuesday July 5, 2022 (Business Wire) +24.41% +17.97%
May-24-22 04:00PM	Anebulo Pharmaceuticals Appoints Kenneth Cundy, Ph.D., as Chief Scientific Officer (Business Wire)
May-11-22 09:00AM	Anebulo Pharmaceuticals Reports Third Quarter Fiscal Year 2022 Financial Results and Recent Updates (Business Wire) -10.29%
Apr-01-22 07:00AM	Anebulo Pharmaceuticals Doses More Than Half of the Subjects in Part A of a Phase 2 Clinical Trial and Provides Guidance on IND Submission (Business Wire)
Feb-11-22 08:00AM	Anebulo Pharmaceuticals Reports Second Quarter Fiscal Year 2022 Financial Results and Recent Updates (Business Wire)
Feb-04-22 04:30AM	We're Hopeful That Anebulo Pharmaceuticals (NASDAQ:ANEB) Will Use Its Cash Wisely (Simply Wall St.) -5.28%
Jan-06-22 07:00AM	Anebulo Pharmaceuticals to Present at the H.C. Wainwright BioConnect Virtual Conference (Business Wire)
07:00AM	Anebulo Pharmaceuticals Appoints Scott L. Anderson as Head of Investor Relations and Public Relations (Business Wire)
Jan-04-22 07:00AM	Anebulo Pharmaceuticals Names Biotechnology Industry Executive Simon Allen as CEO and Director (Business Wire)
Jan-03-22 07:00AM	Anebulo Pharmaceuticals Announces Initiation of Phase 2 Clinical Study Evaluating ANEB-001 for the Treatment of Acute Cannabinoid Intoxication (Business Wire)
Nov-12-21 08:00AM	Anebulo Pharmaceuticals Reports First Quarter Fiscal Year 2022 Financial Results and Provides a Business Update (Business Wire)
Oct-13-21 08:00AM	Anebulo Pharmaceuticals Announces Issuance of U.S. Patent Covering Use of ANEB-001 for the Treatment of Acute Cannabinoid Overdose (Business Wire)
Oct-12-21 08:59AM	Overdose Unknown: How Anebulo Pharmaceuticals Is Working to Solve a Growing Marijuana Overdose Problem (Benzinga)
Oct-05-21 08:00AM	Anebulo Pharmaceuticals to Participate in the Benzinga Cannabis Capital Conference in New York City (Business Wire)
Sep-27-21 07:41AM	The Unintended Consequences of Ever-Increasing Marijuana Potency (Benzinga)
Sep-22-21 04:05PM	Anebulo Pharmaceuticals Reports Fourth Quarter and Fiscal Year 2021 Financial Results and Provides a Business Update (Business Wire)
Sep-20-21 08:13AM	Cannabis Edibles are Leading to More Negative Outcomes in Cannabis Users (Benzinga)
Sep-13-21 08:00AM	CB1 Antagonists as a Solution to the Complicated Problems of Cannabis Over-intoxication (Benzinga)
08:00AM	Anebulo Pharmaceuticals Announces Completion of Manufacturing of ANEB-001 Capsules for Upcoming Phase 2 Clinical Trial (Business Wire)
Sep-07-21 08:00AM	Anebulo Pharmaceuticals to Present at the H.C. Wainwright 23rd Annual Global Investment Conference (Business Wire)
07:04AM	Anebulo is Developing an Antidote to Cannabis Intoxication (Benzinga)
Aug-23-21 08:31AM	Cannabis Legalization is Driving an Increase in Related ER Visits (Benzinga)
Aug-16-21 08:39AM	Alcohol, Cannabis and Synergistic Risk (Benzinga)
Aug-12-21 08:00AM	Anebulo Pharmaceuticals Announces Formation of Scientific Advisory Board, Names First Two Members (Business Wire)
Aug-09-21 08:01AM	Cannabis Over-Intoxication Results in Millions of Visits to the ER per Year (Benzinga)
Aug-08-21 03:23AM	Here's What Anebulo Pharmaceuticals, Inc.'s (NASDAQ:ANEB) Shareholder Ownership Structure Looks Like (Simply Wall St.)
Aug-03-21 02:40PM	The Underappreciated Risk Of Pediatric Cannabis Overdose (Benzinga) -6.17%
Jul-26-21 08:02AM	The Danger of Synthetic Cannabinoids (Benzinga)
Jul-12-21 08:22AM	The Dark Side of Cannabis Legalization and one Biotech Company's Solution (Benzinga) +5.02%
Jun-21-21 04:05PM	Anebulo Pharmaceuticals Reports Recent Business Highlights and Announces Third Quarter Fiscal Year 2021 Financial Results (Business Wire)
May-06-21 08:00PM	Anebulo Pharmaceuticals Announces Pricing of Initial Public Offering (Business Wire)

Anebulo Pharmaceuticals, Inc. is a clinical-stage biotechnology company, which engages in the provision of pharmaceutical services. Its product candidate, Selonabant, is a small molecule antagonist of cannabinoid binding receptor type-1. The company was founded by Joseph F. Lawler on April 23, 2020 and is headquartered in Lakeway, TX.

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

ANEB

Anebulo Pharmaceuticals Inc

Upgrade your FINVIZ experience